|
2022
|
Invention
|
Engineered cpn1 constructs and variants. Provided herein are carboxypeptidase N catalytic subunit... |
|
|
Invention
|
Factor b proteases. Provided herein are engineered proteases of the S1A family that are specific ... |
|
2021
|
Invention
|
Complement factor i-related compositions and methods. Provided herein are Complement Factor I (CF... |
|
2020
|
Invention
|
Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polyp... |
|
|
Invention
|
Modified factor vii polypeptides for subcutaneous administration and on-demand treatment. Provide... |
|
2019
|
Invention
|
Modified urokinase-type plasminogen activator polypeptides and methods of use. Provided are u-PA ... |
|
|
Invention
|
Nicotinic receptor non-competitive antagonists. The present invention relates to compounds that m... |
|
2018
|
Invention
|
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use. Provided are M... |
|
2016
|
Invention
|
Nicotinic receptor non-competitive antagonists.
The present invention relates to compounds that ... |
|
2014
|
Invention
|
Modified factor x polypeptides and uses thereof. Modified therapeutic proteins are provided. In p... |
|
2013
|
Invention
|
Modified factor x polypeptides and uses thereof. Modified Factor X polypeptides, which incl... |
|
2012
|
Invention
|
Modified coagulation factor ix polypeptides and use thereof for treatment.
Provided are modified... |
|
2011
|
Invention
|
Modified factor ix polypeptides and uses thereof. Modified Factor IX (FIX) polypeptides and uses ... |
|
2010
|
Invention
|
3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands. The present... |
|
|
Invention
|
Derivatives of pryidone and use thereof. The present invention provides N-substituted-2(1H) pyrid... |
|
|
Invention
|
Derivatives of pyridone and use thereof. The present invention provides N-substituted-2(1H) pyrid... |
|
2009
|
Invention
|
Factor vii polypeptides that are modified and uses thereof. Modified factor VII polypeptides and ... |
|
2008
|
Invention
|
Modified factor vii polypeptides and uses thereof.
Modified factor VII polypeptides and uses the... |
|
|
Invention
|
Modified factor vii polypetides and uses thereof. Modified factor VII polypeptides and uses there... |
|
2007
|
Invention
|
Methods of generating and screening for proteases with altered specificity.
Disclosed herein are... |
|
|
Invention
|
Use of pyridone derivatives in the prevention or treatment of tissue or organ toxicity induced by... |
|
|
Invention
|
Protease screening methods and proteases identified thereby. Methods for identifying modified pro... |
|
2006
|
Invention
|
Modified proteases that inhibit complement activation. Provided are methods for and compounds for... |
|
2005
|
Invention
|
Mt-sp1 polynucleotides and polypeptides. This invention provides a novel membrane-type serine pro... |
|
|
Invention
|
Administration of neutral endopeptidase to treat inflammatory bowel disease.
Administration of r... |
|
|
Invention
|
Administration of neutral endopeptidase to treat inflammatory bowel disease. Administration of re... |
|
|
Invention
|
Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1. MT-SP1 mutein proteases with al... |
|
2003
|
Invention
|
Derivatives of pyridone and the use of them. The present invention provides N-substituted-2(1H) p... |
|
|
Invention
|
Methods of generating and screening for proteases with altered specificity. Disclosed herein are ... |
|
|
Invention
|
Methods of generating and screening for proteases with altered specificity. Disclosed herei... |
|
1999
|
Invention
|
Membrane type serine protease 1 (mt-sp1) and uses thereof. This invention provides a novel membra... |
